Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
43M
-
Shares change
-
+2.1M
-
Total reported value, excl. options
-
$557M
-
Value change
-
+$27.1M
-
Put/Call ratio
-
1.87
-
Number of buys
-
61
-
Number of sells
-
-39
-
Price
-
$12.97
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2019
131 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43M shares
of 105M outstanding shares and own 41.13% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5.7M shares), ArrowMark Colorado Holdings LLC (4.31M shares), BlackRock Inc. (3.53M shares), FRANKLIN RESOURCES INC (3.51M shares), Essex Woodlands Management, Inc. (3.34M shares), JPMORGAN CHASE & CO (2.47M shares), Bank of New York Mellon Corp (2.25M shares), VANGUARD GROUP INC (2.25M shares), ALLIANCEBERNSTEIN L.P. (2.04M shares), and Capital World Investors (1.69M shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.